{"pmid":32451256,"pmcid":"PMC7211657","title":"COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?","text":["COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?","J Infect Public Health","Thangaraju, Pugazhenthan","Gurunthalingam, Meenalotchini Prakash","Venkatesan, Sajitha","Thangaraju, Eswaran","32451256"],"journal":"J Infect Public Health","authors":["Thangaraju, Pugazhenthan","Gurunthalingam, Meenalotchini Prakash","Venkatesan, Sajitha","Thangaraju, Eswaran"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451256","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jiph.2020.05.006","topics":["Treatment"],"weight":1,"_version_":1667983494599409666,"score":9.490897,"similar":[{"pmid":32347974,"title":"Metformin and COVID-19: A novel deal of an Old Drug.","text":["Metformin and COVID-19: A novel deal of an Old Drug.","In 2002, China witnessed the emergence of a severe acute respiratory disease caused by coronavirus SARS-CoV. Ten years later in 2012 a new version of the virus appeared in the Middle East known as Middle East Respiratory Syndrome Coronavirus MERS-CoV. At the end of 2019, the Chinese Center for Disease Control and Prevention (China CDC) recorded a pneumonia of unknown causes. Epidemiologically, the pneumonia was linked to a wet animal and seafood wholesale market in Wuhan, Hubei Province, China, later Known by COVID-19. The COVID-19 is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now the total number of confirmed cases is 2,709,483 in over 225 countries around the world. A recent report indicates that obesity may responsible for increasing the mortality of COVID-19 in Italy rather than in China. Here we would like to shed light on a new suggestion to decrease the mortality rate of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","El-Arabey, Amr Ahmed","Abdalla, Mohnad","32347974"],"abstract":["In 2002, China witnessed the emergence of a severe acute respiratory disease caused by coronavirus SARS-CoV. Ten years later in 2012 a new version of the virus appeared in the Middle East known as Middle East Respiratory Syndrome Coronavirus MERS-CoV. At the end of 2019, the Chinese Center for Disease Control and Prevention (China CDC) recorded a pneumonia of unknown causes. Epidemiologically, the pneumonia was linked to a wet animal and seafood wholesale market in Wuhan, Hubei Province, China, later Known by COVID-19. The COVID-19 is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now the total number of confirmed cases is 2,709,483 in over 225 countries around the world. A recent report indicates that obesity may responsible for increasing the mortality of COVID-19 in Italy rather than in China. Here we would like to shed light on a new suggestion to decrease the mortality rate of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["El-Arabey, Amr Ahmed","Abdalla, Mohnad"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347974","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25958","keywords":["covid-19","diabetic","metformin","obesity","older","pneumonia"],"locations":["China","Wuhan","Hubei","China","Italy","China"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"e_drugs":["Metformin"],"topics":["Treatment"],"weight":1,"_version_":1666138494928420865,"score":51.218117},{"pmid":32362051,"title":"Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight.","text":["Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight.","Dermatol Ther","Grandolfo, Mauro","Romita, Paolo","Bonamonte, Domenico","Cazzato, Gerardo","Hansel, Katharina","Stingeni, Luca","Conforti, Claudio","Giuffrida, Roberta","Foti, Caterina","32362051"],"journal":"Dermatol Ther","authors":["Grandolfo, Mauro","Romita, Paolo","Bonamonte, Domenico","Cazzato, Gerardo","Hansel, Katharina","Stingeni, Luca","Conforti, Claudio","Giuffrida, Roberta","Foti, Caterina"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32362051","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dth.13499","keywords":["covid-19","dress syndrome","drug reaction with eosinophilia and systemic symptoms","adverse drug reaction","hydroxychloroquine"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138495953928193,"score":47.139713},{"pmid":32415419,"title":"Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?","text":["Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?","Hydroxychloroquine (HCQ) is an old medication for malaria. In addition to handling this parasitic disease, HCQ is also used to treat a number of autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus when other medications are not effective. Recently a new viral infection (COVID-19) is rocking the entire world so much that it has already taken more than 200,000 lives throughout the world within the last two months and the World Health Organization was forced to declare it as a pandemic on March 11, 2020. Interestingly, some reports indicate that this wonder drug may be also beneficial for COVID-19 and accordingly, many clinical trials have begun. Here, we discuss different modes of action (anti-inflammatory, antioxidant, inhibition of endosomal acidification, suppression of angiotensin-converting enzyme 2 or ACE2 glycosylation, etc.) of HCQ that might be responsible for its possible anti-COVID-19 effect. On the other hand, this review also makes an honest attempt to delineate mechanisms (increase in vasoconstriction, inhibition of autophagy, depletion of T cells, etc.) indicating how it may aggravate certain conditions and why caution should be taken before granting widespread repurposing of HCQ for COVID-19. Graphical Abstract.","J Neuroimmune Pharmacol","Pahan, Priyanka","Pahan, Kalipada","32415419"],"abstract":["Hydroxychloroquine (HCQ) is an old medication for malaria. In addition to handling this parasitic disease, HCQ is also used to treat a number of autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus when other medications are not effective. Recently a new viral infection (COVID-19) is rocking the entire world so much that it has already taken more than 200,000 lives throughout the world within the last two months and the World Health Organization was forced to declare it as a pandemic on March 11, 2020. Interestingly, some reports indicate that this wonder drug may be also beneficial for COVID-19 and accordingly, many clinical trials have begun. Here, we discuss different modes of action (anti-inflammatory, antioxidant, inhibition of endosomal acidification, suppression of angiotensin-converting enzyme 2 or ACE2 glycosylation, etc.) of HCQ that might be responsible for its possible anti-COVID-19 effect. On the other hand, this review also makes an honest attempt to delineate mechanisms (increase in vasoconstriction, inhibition of autophagy, depletion of T cells, etc.) indicating how it may aggravate certain conditions and why caution should be taken before granting widespread repurposing of HCQ for COVID-19. Graphical Abstract."],"journal":"J Neuroimmune Pharmacol","authors":["Pahan, Priyanka","Pahan, Kalipada"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415419","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s11481-020-09923-w","keywords":["autophagy","covid-19","hydroxychloroquine","hypertension","inflammation","oxidative stress"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666994545930272768,"score":44.105038},{"pmid":32426897,"title":"Heparin - an old drug with multiple potential targets in Covid-19 therapy.","text":["Heparin - an old drug with multiple potential targets in Covid-19 therapy.","A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin.","J Thromb Haemost","Lindahl, Ulf","Li, Jin-Ping","32426897"],"abstract":["A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin."],"journal":"J Thromb Haemost","authors":["Lindahl, Ulf","Li, Jin-Ping"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426897","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jth.14898","locations":["heparin","heparin","Heparin"],"e_drugs":["Heparin","Polysaccharides","Heparitin Sulfate","Heparin, Low-Molecular-Weight"],"topics":["Treatment"],"weight":1,"_version_":1667252837926567937,"score":42.217308},{"pmid":32472681,"title":"Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.","text":["Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.","Rheumatology (Oxford)","Piantoni, Silvia","Patroni, Andrea","Toniati, Paola","Furloni, Roberto","Franceschini, Franco","Andreoli, Laura","Scarsi, Mirko","32472681"],"journal":"Rheumatology (Oxford)","authors":["Piantoni, Silvia","Patroni, Andrea","Toniati, Paola","Furloni, Roberto","Franceschini, Franco","Andreoli, Laura","Scarsi, Mirko"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472681","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/rheumatology/keaa217","topics":["Treatment"],"weight":1,"_version_":1668255193465094145,"score":41.469868}]}